Health Canada’s use of its priority review process for new drugs: a cohort study Joel Lexchin1,2,3 To cite: Lexchin J. Health Canada’s use of its priority review process for new drugs: a cohort study. BMJ Open 2015;5:e006816. doi:10.1136/bmjopen-2014-006816 ▸ Prepublication history for this paper is available online. To view these files please visit the journal onlin
Journal Article;BACKGROUND In Spain, hospital medicines are assessed and selected by local Pharmacy...
This is associated with a manuscript submitted for peer review.Context: In 1996, the American Thyroi...
The document attached has been archived with permission from the editor of the Medical Journal of Au...
Supplemental material, Supplemental Material1 for Health Canada’s Use of its Notice of Compliance Wi...
Supplemental material, Supplemental Material2 for Health Canada’s Use of its Notice of Compliance Wi...
Objectives: This study examines the use of accelerated approval pathways by Health Canada over the p...
Supplemental material, Supplemental Material3 for Health Canada’s Use of its Notice of Compliance Wi...
Objectives: This study examines the characteristics of studies that Health Canada uses to grant full...
Objectives Investigate if the recommendations by the Common Drug Review (CDR) and the pa...
Objectives: Examine the probability of new active substances (NASs) approved in Canada between 1 Jan...
Directive and doctors ’ health: a systematic review of the available epidemiological evidence. BMJ O...
Supplemental material, sj-pdf-1-cph-10.1177_17151635231202980 for Patient perspectives on the enviro...
AbstractObjectivesMany Canadians use prescription medicines that are unnecessary or that can lead to...
Making drug data more transparent Joel Lexchin discusses the impor-tance of informing people about m...
Inaccessibility of drug reports When new drugs are launched,physicians must have access to the rando...
Journal Article;BACKGROUND In Spain, hospital medicines are assessed and selected by local Pharmacy...
This is associated with a manuscript submitted for peer review.Context: In 1996, the American Thyroi...
The document attached has been archived with permission from the editor of the Medical Journal of Au...
Supplemental material, Supplemental Material1 for Health Canada’s Use of its Notice of Compliance Wi...
Supplemental material, Supplemental Material2 for Health Canada’s Use of its Notice of Compliance Wi...
Objectives: This study examines the use of accelerated approval pathways by Health Canada over the p...
Supplemental material, Supplemental Material3 for Health Canada’s Use of its Notice of Compliance Wi...
Objectives: This study examines the characteristics of studies that Health Canada uses to grant full...
Objectives Investigate if the recommendations by the Common Drug Review (CDR) and the pa...
Objectives: Examine the probability of new active substances (NASs) approved in Canada between 1 Jan...
Directive and doctors ’ health: a systematic review of the available epidemiological evidence. BMJ O...
Supplemental material, sj-pdf-1-cph-10.1177_17151635231202980 for Patient perspectives on the enviro...
AbstractObjectivesMany Canadians use prescription medicines that are unnecessary or that can lead to...
Making drug data more transparent Joel Lexchin discusses the impor-tance of informing people about m...
Inaccessibility of drug reports When new drugs are launched,physicians must have access to the rando...
Journal Article;BACKGROUND In Spain, hospital medicines are assessed and selected by local Pharmacy...
This is associated with a manuscript submitted for peer review.Context: In 1996, the American Thyroi...
The document attached has been archived with permission from the editor of the Medical Journal of Au...
DOI
Add to ORKG